CD274 and non-small cell lung carcinoma: In on-squamous NSCLC patients, regardless of the PD-L1 expression, compared with bevacizumab + chemotherapy, the checkpoint inhibitor atezolizumab combined with bevacizumab/chemotherapy is more effective.[24] Still, due to related side effects, it is not a preferred solution.